GB2551684A - Advances in bruise amelioration - Google Patents
Advances in bruise amelioration Download PDFInfo
- Publication number
- GB2551684A GB2551684A GB1511189.1A GB201511189A GB2551684A GB 2551684 A GB2551684 A GB 2551684A GB 201511189 A GB201511189 A GB 201511189A GB 2551684 A GB2551684 A GB 2551684A
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- bruise
- concentration
- amelioration
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000034656 Contusions Diseases 0.000 title claims abstract description 39
- 208000034526 bruise Diseases 0.000 title claims description 32
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 230000035602 clotting Effects 0.000 claims abstract description 7
- 206010053567 Coagulopathies Diseases 0.000 claims abstract description 6
- 239000008168 almond oil Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 5
- 239000008169 grapeseed oil Substances 0.000 claims abstract description 5
- 239000003605 opacifier Substances 0.000 claims abstract description 5
- 241000208680 Hamamelis mollis Species 0.000 claims abstract description 4
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 4
- 239000002243 precursor Substances 0.000 claims abstract description 4
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 4
- 239000011712 vitamin K Substances 0.000 claims abstract description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 4
- 229940046010 vitamin k Drugs 0.000 claims abstract description 4
- 229940118846 witch hazel Drugs 0.000 claims abstract description 4
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 3
- 241000086254 Arnica montana Species 0.000 claims abstract 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- 229940041616 menthol Drugs 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- 244000144725 Amygdalus communis Species 0.000 claims 1
- 235000011437 Amygdalus communis Nutrition 0.000 claims 1
- 235000020224 almond Nutrition 0.000 claims 1
- 239000004205 dimethyl polysiloxane Substances 0.000 claims 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 1
- -1 polydimethylsiloxane Polymers 0.000 claims 1
- 229920002050 silicone resin Polymers 0.000 claims 1
- 235000019489 Almond oil Nutrition 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 10
- 208000014674 injury Diseases 0.000 description 7
- 230000008733 trauma Effects 0.000 description 7
- 239000006071 cream Substances 0.000 description 5
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 210000000264 venule Anatomy 0.000 description 3
- 241000208983 Arnica Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000001102 lavandula vera Substances 0.000 description 2
- 235000018219 lavender Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229920006268 silicone film Polymers 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108010063290 Aquaporins Proteins 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition for the amelioration or treatment of bruises, the composition comprises a water replacing compound, preferably glycerol, an opacifier, preferably triglycerides present in a combination of almond oil and grape seed oil, and a silicone based film forming agent, preferably DC 593. In optional embodiments the composition additionally includes one or more of a clotting precursor, such as vitamin K, an astringent, such as Witch Hazel, an anti-inflammatory, such as NAB Arnica, or a clot buster, such as Ginko Biloba.
Description
(71) Applicant(s):
Christopher Louis Ives
Rose Farm, Stonely Green, NANTWICH, Cheshire, CW5 8QA, United Kingdom
SkinGen International
Dane Mill Business Centre, Broadhurst Lane, CONGLETON, Cheshire, CW12 1LA, United Kingdom (72) Inventor(s):
Christopher Louis Ives David Bryant (74) Agent and/or Address for Service:
Christopher Louis Ives
Rose Farm, Stonely Green, NANTWICH, Cheshire, CW5 8QA, United Kingdom (51) INT CL:
A61K 8/92 (2006.01) A61K 45/00 (2006.01)
A61Q 19/00 (2006.01) (56) Documents Cited:
WO 2004/022117 A1 CN 104288828 A US 20090155325 A1 (58) Field of Search:
INT CLA61K, A61Q
Other: EPODOC; WPI; TXTE; BIOSIS; MEDLINE (54) Title of the Invention: Advances in bruise amelioration Abstract Title: Compositions for bruise amelioration (57) A composition for the amelioration or treatment of bruises, the composition comprises a water replacing compound, preferably glycerol, an opacifier, preferably triglycerides present in a combination of almond oil and grape seed oil, and a silicone based film forming agent, preferably DC 593. In optional embodiments the composition additionally includes one or more of a clotting precursor, such as vitamin K, an astringent, such as Witch Hazel, an antiinflammatory, such as NAB Arnica, or a clot buster, such as Ginko Biloba.
Advances in bruise amelioration
Background
Bruises are typically caused by trauma, often by absorption of direct mechanical energy (a physical blow) by penetration of the skin and subdermal tissues by random sharp objects or controlled objects such as needles and scalpels (e.g. injections, dermal infusions or surgery). In each case a typical pattern of events occurs with, on a macroscale, disruption to local capillaries and venules and, on a microscale, damage to cells and extracellular matrix materials. The disruption of the capillaries and venules will result in red blood cells haemorrhaging, the cells being released into the interstitial space. The latter combined with local nerve responses and release locally of molecules such as histamine will cause local vasodilation resulting visually in initial skin reddening and then as red cells and their haemoglobin breakdown products build up more dramatic changes to skin colour. Over time, once haemostasis has been restored, initially through the fundamental clotting mechanisms triggered through the extrinsic and intrinsic pathways, the haemorrhaged red cells will be broken down and the haemoglobin released will be converted to bilirubin and biliverdin, both colourful molecules adding tinges of yellow and purple to the visual appearance of the skin (the classic bruise presentation). In the final phases the inflammatory response will attract a range of phagocytic cells and fibroblasts which will eventually clear the debris and lay down a new extra cellular matrix for subdermal tissue reconstruction. It is also relevant to note that age related changes may produce a bruise like effect known as senile purpura that maybe controlled by some of the same physiological drivers seen in trauma induced bruising. In addition to the above elements bruise formation maybe associated with some pain and discomfort not only at the time of the immediate trauma but also once bruise formation has been initiated and progresses.
Attempts to treat or cosmetically mask bruising have resulted in a range of skin potions targeted at various single or multiple elements of the physiological drivers involved. The novelty of this invention is that it seeks to combine a range of natural and synthetic compounds so that they work synergistically to direct the physiology and the outcome of bruising, ameliorating the biological impact and improving the skin appearance and in some manifestations of the invention also reducing any pain. The timing and composition of the treatment application may vary according to whether the bruise has been initiated, if it is developing or whether haemostasis has been achieved.
References:David Funt ;Plastic Surgical Nursing January/March 2015;Volume 35;lssue l;pp: 13-32 ;Dermai Fillers in Aesthetics: An Overview of Adverse Events and Treatment Approaches
July 2011 VOLUME 10 » ISSUE 7 Copyright © 2011 Journal of Drugs in Dermatology
Berlin MD, Eisenberg,; Drugs Dermatol.2011;10(7):718-722.A Randomized, Piacebo-Controlied, Double-Blind Study to Evaluate the Efficacy of a Citrus Bioflavanoid Blend in the Treatment of Senile Purpura
Fortschr Med. 1977 Jun 16;95(23):1557-60;Controlled study on the efficacy of external treatment in surface-near thrombophlebitisl.Schedel F, Hennemann B, Reindl P.
Am J Health System Pharm Vol 64 Dec 1 2007
Cohen J;The Role of Topical Vitamin K Oxide Gel in the Resolution of Post procedural Purpura; J Drug Derm; 2009; 8: 1020-1025
US Patent 2013210777(al) 2011-02-17 Amelioration of the appearance of bruises US Patent 2O11144215(A1) 2006-05-26 Bruise amelioration composition and method of use
Eccles R. Menthol and related cooling compounds J. Pharm. Pharmacol. 1994 46:618-630
The Invention
Understanding the mechanism of bruise development identifies possibilities for bruise amelioration and cosmetic improvement. The composition of the treatment cream applied will depend upon the status of the skin, namely immediately prior to trauma, with the bruise not yet initiated, bruise pathway initiated by trauma/insult/other, internal haemostasis achieved and bruise repair pathway progressing. In this invention a choice of bruise amelioration treatment is proposed and the treatment chosen may depend upon the state of bruise progression. If the bruise has reached equilibrium and is under repair then the optimum treatment is to displace the interstitial fluid, the blood and detritus which involves application of a skin cream the main components of which are glycerol and water, which pass through specific channels in the skin cells(aquaporin channels) into the interstitial space and will tend to displace any blood contaminated interstitial fluid driving it to be taken up by the lymphatics and venules. The other key components of the cream are skin opacifiers designed to soften the skin and cause it to become more visually opaque so the external visible signs of bruising are reduced. Finally a silicone film former is added which when applied to the skin controls the microenvironment of the skin by reducing the skin permeability further hydrating and opacifying the skin cells as well as helping the displacement of any sub dermal fluid .
In a further development of the treatment, and for use immediately prior to or immediately post trauma, a skin cream is applied that contains a series of agents each simultaneously targeting a driver of the bruise formation and or of the elements that cause the typical appearance of the bruise site. Initially the first aim is to stop any haemorrhage and leaking of red blood cells by activation of the usual clotting mechanisms. This may be combined with an astringent and an anti-inflammatory to damp down drivers of swelling and redness along with a clot buster to inhibit clot formation or break down formed clots.
In addition to these elements if there is pain associated with the bruise this may be alleviated by the addition of menthol to the cream in a concentration of 1-2%. Menthol gives both a sensation of cooling as well as having a local anaesthetic effect. Both effects are probably driven by the effect of menthol on the movement of calcium ions influencing the thermos receptors and the nociceptors.
Combining all these components that influence different aspects of bruise development and any pain or consequent cosmetic effects can have benefits. These components potentially working synergistically with the other main components of the cream the glycerol, water and silicone film former to ameliorate the impact of trauma on initial bruise formation and spread as well as ameliorating the short and long term impact of bruise components on cosmetic appearance and pain.
A typical manifestation of the creams is given in the examples below:
Example 1
Bruise MD
| Amelioration Formulation | wt/wt % |
| Glycerol | 52.1 |
| Almond Oil | 10 |
| Grapeseed Oil | 10 |
| DC 593 | 10 |
| Aqua | 14.4 |
| Ultrez 10 | 1.5 |
| Lavender | 0.3 |
| Phenoxyethanol | 1 |
| Example 2 | |
| Bruise MD Amelioration Formulation + treatment | wt/wt % |
| Glycerol | 49 |
| Almond Oil | 8 |
| Grapeseed Oil | 8 |
| Shea butter | 2 |
| Tocopherol Vit E | 2 |
| Retinyl Palmitate Vit A | 2 |
| Vitamin K | 0.1 |
| Witch Hazel | 2 |
| NAB Arnica | 1 |
| DC 593 | 8 |
| Aqua | 14.4 |
| Ultrez 10 | 1.5 |
| Lavender | 0.3 |
| Phenoxyethanol | 1 |
| Triethanolamine | 0.7 |
Example 3
Bruise MD
Amelioration formulation + treatment and pain relief %
| Glycerol | 58.5 |
| Almond Oil | 10 |
| DC 593 | 10 |
| Aqua | 16 |
| Ultrez 10 | 1.5 |
| Phenoxyethanol | 1 |
| Triethanolamine | 1 |
| menthol | 2 |
| Total | 100 |
Claims (13)
1. A bruise amelioration treatment composition that contains • A water displacing molecule • A skin opacifier • A silicone based film forming agent
2. A treatment as in 1 above where the water displacing molecule is glycerol in a concentration of 40-60%
3. A treatment as in 1 above where the skin opacifier is in the form of triglycerides found in a mixture of almond and grapeseed oils in a concentration of 10-30%
4. A treatment as in 1 above where the silicone based film former is DC 593 a high molecular weight silicone resin in polydimethylsiloxane in a concentration of 1-5%
5. A bruise amelioration treatment composition as in 1 above that in addition contains one, several or all of the following • A clotting precursor • An astringent • An anti-inflammatory • A clot buster
6. A treatment as in 5 above where the clotting precursor is vitamin K in a concentration of 0.1 3%
7. A treatment as in 5 above where the astringent is Witch Hazel in a concentration of 1-5%
8. A treatment as in 5 above where the anti-inflammatory is NAB Arnica in a concentration of 1-5%
9. A treatment as in 5 above where the clot buster is Ginko Biloba
10. A bruise amelioration treatment as in 5 above that in addition contains a cooling and pain relieving element
11. A bruise amelioration treatment as in 10 where the cooling and pain relief is provide by menthol
12. A bruise amelioration treatment composition as in 1 above where the viscosity is in the range 10,000 to 50,000 centistokes
13. A bruise amelioration treatment composition as in 5 above where the viscosity is in the range 10,000 to 50,000 centistokes
Intellectual
Property
Office
Application No: Claims searched:
GB1511189.1
1-13
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1511189.1A GB2551684A (en) | 2015-06-25 | 2015-06-25 | Advances in bruise amelioration |
| PCT/GB2016/000125 WO2016207586A1 (en) | 2015-06-25 | 2016-06-22 | Advances in bruise amelioration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1511189.1A GB2551684A (en) | 2015-06-25 | 2015-06-25 | Advances in bruise amelioration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201511189D0 GB201511189D0 (en) | 2015-08-12 |
| GB2551684A true GB2551684A (en) | 2018-01-03 |
Family
ID=53872213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1511189.1A Withdrawn GB2551684A (en) | 2015-06-25 | 2015-06-25 | Advances in bruise amelioration |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2551684A (en) |
| WO (1) | WO2016207586A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022117A1 (en) * | 2002-09-09 | 2004-03-18 | Kimberly-Clark Worldwide, Inc. | Moisturizing and lubricating composition |
| US20090155325A1 (en) * | 2007-12-14 | 2009-06-18 | Kimberly-Clark Worldwide, Inc. | Formulation and products for promoting skin cleanliness and health |
| CN104288828A (en) * | 2014-10-29 | 2015-01-21 | 广西信业生物技术有限公司 | Medical biological scar-inhibiting rhytidectomy dressing and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0212749D0 (en) * | 2002-06-01 | 2002-07-10 | Boots Co Plc | Personal care compositions |
| US9023406B2 (en) * | 2011-02-17 | 2015-05-05 | Dr. Holmquist Healthcare, LLC | Amelioration of the appearance of bruises |
| JP5207426B2 (en) * | 2006-06-30 | 2013-06-12 | 学校法人神奈川大学 | Cosmetics and method for producing the same |
-
2015
- 2015-06-25 GB GB1511189.1A patent/GB2551684A/en not_active Withdrawn
-
2016
- 2016-06-22 WO PCT/GB2016/000125 patent/WO2016207586A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022117A1 (en) * | 2002-09-09 | 2004-03-18 | Kimberly-Clark Worldwide, Inc. | Moisturizing and lubricating composition |
| US20090155325A1 (en) * | 2007-12-14 | 2009-06-18 | Kimberly-Clark Worldwide, Inc. | Formulation and products for promoting skin cleanliness and health |
| CN104288828A (en) * | 2014-10-29 | 2015-01-21 | 广西信业生物技术有限公司 | Medical biological scar-inhibiting rhytidectomy dressing and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016207586A1 (en) | 2016-12-29 |
| GB201511189D0 (en) | 2015-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11241405B2 (en) | Methods to enhance a non-surgical medical treatment | |
| Bhargava et al. | Combination therapy using subcision, needling, and platelet‐rich plasma in the management of grade 4 atrophic acne scars: a pilot study | |
| CN108785122A (en) | A kind of anti-acne conveys nano-composition and its preparation method and application altogether | |
| JP2011522831A (en) | Acne treatment composition containing nanosilver and use thereof | |
| US20110129552A1 (en) | Acne Treatment | |
| KR20130134532A (en) | Multilayer liquid crystal vesicle for relieving skin irritation and for recovering skin barrier, and cosmetic composition comprising the same | |
| JP2021509123A (en) | Topical skin care composition | |
| Mahjoub et al. | Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: a review | |
| CA3008532A1 (en) | Composition comprising an ambora extract and a green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant pruritus and senile pruritus | |
| EP1541126A1 (en) | Cosmetic and dermatological composition comprising a combination of a green colouring agent and an antiinflammatory agent | |
| US20160296583A1 (en) | Methods and compounds for intensive skin repair and healing including active organic and synthetic compounds | |
| KR102611907B1 (en) | The functional cosmetic composition containing Spicule Extract and a manufacturing method thereof | |
| CN104434642A (en) | Whitening and moisturizing gel for after-sun repairing and preparation method thereof | |
| BRPI0622226A2 (en) | skin whitening composition for hyperpigmented skin | |
| CN112716838A (en) | Rose essential oil eye repairing and tightening essence and preparation method thereof | |
| US20190151394A1 (en) | Prebiotic Acne Treatment | |
| GB2551684A (en) | Advances in bruise amelioration | |
| ES2409353T3 (en) | Dermatological composition for the treatment of bedsores | |
| WO2016028811A1 (en) | Pain relieving system | |
| ES2932359T3 (en) | Formulation based on N-acetylcysteine and urea for the treatment of dermatological disorders | |
| DE102013018565A1 (en) | Personal care products and their use | |
| RU2780260C1 (en) | Cosmetic for skin | |
| US20260021161A1 (en) | Silk peptides topical formulations and methods of their use | |
| Farrisa | Cosmeceuticals for Acne and Rosacea | |
| US20260007584A1 (en) | Composition for use in concealing, healing, and/or moisturing a bruise |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) | ||
| S20A | Reinstatement of application (sect. 20a/patents act 1977) |
Free format text: REQUEST FOR REINSTATEMENT FILED Effective date: 20170915 Free format text: REQUEST FOR REINSTATEMENT ALLOWED Effective date: 20171121 |
|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |